MAY 24, 2019 4:11 PM PDT

First PI3K Inhibitor for Breast Cancer

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration has approved Piqray (alpelisib) tablets, to be used in conjunction with FDA-approved endocrine therapy fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer.

“Piqray is the first PI3K inhibitor to demonstrate a clinically meaningful benefit in treating patients with this type of breast cancer. The ability to target treatment to a patient’s specific genetic mutation or biomarker is becoming increasingly common in cancer treatment, and companion diagnostic tests assist oncologists in selecting patients who may benefit from these targeted treatments,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

“For this approval, we employed some of our newer regulatory tools to streamline reviews without compromising the quality of our assessment. This drug is the first novel drug approved under the Real-Time Oncology Review pilot program. We also used the updated Assessment Aid, a multidisciplinary review template that helps focus our written review on critical thinking and consistency and reduces time spent on administrative tasks.”

It’s important to note that metastatic breast cancer is breast cancer that has reached to other organs in the body most notably the bones, lungs, liver or brain. When breast cancer is hormone-receptor-positive, patients receive anti-hormonal endocrine therapy either alone or in combination with other medicines.

Piqray is a Trademark of the biopharmaceutical company, Novartis

With the efficacy of Piqray and fulvestrant, it can significantly prolong progression-free survival in patients whose tumors had PIK3CA mutation.

Some common side-effects of Piqray include high blood glucose levels, an increase in creatinine, diarrhea, rash, decrease in white blood cell count in the blood, elevated liver enzymes, nausea, fatigue, low red blood cell count, increase in pancreatic enzymes, decreased appetite, stomatitis, vomiting, weight loss, low calcium levels, and hair loss.

Source: FDA

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JAN 19, 2021
Immunology
Food Allergies Be Gone: Nanoparticles Call for an Immune Ceasefire
JAN 19, 2021
Food Allergies Be Gone: Nanoparticles Call for an Immune Ceasefire
Milk, eggs, peanuts, tree nuts, wheat, soy, fish, and shellfish—these foods are among the most unwanted list for t ...
FEB 22, 2021
Microbiology
A Nasal Spray That Seems to Prevent the Spread of COVID-19
FEB 22, 2021
A Nasal Spray That Seems to Prevent the Spread of COVID-19
Reporting in Science, researchers have created an antiviral nasal spray that could help us get the COVID-19 pandemic und ...
FEB 12, 2021
Drug Discovery & Development
Compound Reverses ALS Neuron Damage
FEB 12, 2021
Compound Reverses ALS Neuron Damage
Scientists at Northwestern University identify the first compound that removes the ongoing degeneration of upper motor n ...
FEB 10, 2021
Drug Discovery & Development
Snail Venom Treats Malaria
FEB 10, 2021
Snail Venom Treats Malaria
In a first-of-its-kind study, scientists from Florida Atlantic University's Schmidt College of Medicine in collabora ...
MAR 21, 2021
Microbiology
Potent Drug Rapidly Clears Drug-Resistant Gonorrhea in Mouse Model
MAR 21, 2021
Potent Drug Rapidly Clears Drug-Resistant Gonorrhea in Mouse Model
A mouse model has shown that it's possible to clear a multi-drug resistant gonorrhea with only one dose of antibioti ...
APR 17, 2021
Drug Discovery & Development
Nanofiber-Based Drug Treats Inflammation
APR 17, 2021
Nanofiber-Based Drug Treats Inflammation
Researchers at Duke University worked on creating a self-assembling nanomaterial-based drug that can help address damage ...
Loading Comments...